---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-038835"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-12-29T23:59:59+00:00"
generated_at: "2026-05-16T12:06:56.550404+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals eliminates all balance sheet debt by converting $5.4M to equity

## Summary
- Repaid remaining $5.4M debt to Anson Funds via equity conversion of common stock; no warrants or repricing mechanisms.
- Original Anson loan was $16.2M; Company expects Dec 31 balance sheet to reflect zero convertible debt.
- Debt-free capital structure positions NRx for accelerated growth with potential 2026 drug approvals and clinic expansions.
- Press release dated Dec 2, 2025; Debt Cancellation Agreement executed Dec 29, 2025.

## SEC filing metadata
- accession: 0001437749-25-038835
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-12-29T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925038835/0001437749-25-038835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925038835/nrxp20251229_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-038835
- JSON: https://secwatch.observer/filing/0001437749-25-038835.json
- Plain text: https://secwatch.observer/filing/0001437749-25-038835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.